Philip M Spanheimer
Overview
Explore the profile of Philip M Spanheimer including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
57
Citations
464
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Wang Y, Haase S, Whitman A, Beltran A, Spanheimer P, Brunk E
bioRxiv
. 2025 Mar;
PMID: 40027670
Understanding how individual cancer cells adapt to drug treatment is a fundamental challenge limiting precision medicine cancer therapy strategies. While single-cell technologies have advanced our understanding of cellular heterogeneity, efforts...
2.
Kakati R, Whitman A, Haase S, Szenasi A, Thai C, Brunk E, et al.
bioRxiv
. 2025 Feb;
PMID: 39975402
Significance: Vandetanib enhances sensitivity to tamoxifen in ER+ breast cancer cells by reprograming kinase signaling networks, which can be used to select patients most likely to respond and develop more...
3.
Regner M, Garcia-Recio S, Thennavan A, Wisniewska K, Mendez-Giraldez R, Felsheim B, et al.
Cell Genom
. 2025 Feb;
5(2):100765.
PMID: 39914387
Annotation of cis-regulatory elements that drive transcriptional dysregulation in cancer cells is critical to understanding tumor biology. Herein, we present matched chromatin accessibility (single-cell assay for transposase-accessible chromatin by sequencing...
4.
Trembath H, Spanheimer P
Cancer Res
. 2025 Feb;
85(3):407-409.
PMID: 39891927
Racial disparities in cancer outcomes are well documented across tumor types. For patients with breast cancer, Black women are more likely to present with more aggressive molecular features and more...
5.
Selfridge J, Schrank Z, Agala C, Ollila D, Gallagher K, Casey D, et al.
Ann Surg Oncol
. 2024 Dec;
32(3):2070-2078.
PMID: 39674862
Background: There is limited data regarding sentinel lymph node biopsy (SLNB) after neoadjuvant chemotherapy (NAC) for cN3b patients, who present with both axillary and ipsilateral internal mammary node involvement. We...
6.
East M, Sprung R, Okumu D, Olivares-Quintero J, Joisa C, Chen X, et al.
bioRxiv
. 2024 Oct;
PMID: 39464086
The kinome is a dynamic system of kinases regulating signaling networks in cells and dysfunction of protein kinases contributes to many diseases. Regulation of the protein expression of kinases alters...
7.
Mukherjee A, Kakati R, Van Alsten S, Laws T, Ebbs A, Hollern D, et al.
JCI Insight
. 2024 Oct;
9(23).
PMID: 39418101
Despite proven therapy options for estrogen receptor-positive (ER+) breast tumors, a substantial number of patients with ER+ breast cancer exhibit relapse with associated metastasis. Loss of expression of RasGAPs leads...
8.
Thai C, An S, Haase C, Selfridge J, Agala C, Gallagher K, et al.
Res Sq
. 2024 Sep;
PMID: 39281884
Purpose: Residual cancer burden (RCB) index after neoadjuvant chemotherapy (NAC) is highly prognostic in patients with breast cancer (BC) but does not account for subtype or the precise impact of...
9.
Thai C, An S, Haase C, Selfridge J, Agala C, Spanheimer P
Breast Cancer Res Treat
. 2024 Sep;
209(2):315-322.
PMID: 39278893
Purpose: Residual cancer burden (RCB) index after neoadjuvant chemotherapy (NAC) is highly prognostic in patients with breast cancer (BC) but does not account for subtype or the precise impact of...
10.
Rosenberger L, Thomas S, Hieken T, Gallagher K, Spanheimer P, Neuman H, et al.
Breast Cancer Res Treat
. 2024 Sep;
209(2):275-282.
PMID: 39269552
Purpose: Germline genetic mutations in women with phyllodes tumors (PT) are understudied, although some describe associations of PT with various mutations. We sought to determine the prevalence of pathogenic/likely pathogenic...